Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy

被引：19

作者：

Warlick, CA ^{[1
]}

Allaf, ME ^{[1
]}

Carter, HB ^{[1
]}

机构：

[1] Johns Hopkins Univ Hosp, Dept Urol, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2006年 / 24卷 / 01期

关键词：

expectant management; prostate cancer; curative intervention;

D O I：

10.1016/j.urolonc.2005.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Expectant treatment with Curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient C selection, (2) adequate surveillance strategies, zinc (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density < 0.15 ng/ml/cm(3), and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in Use. Outcomes data are still required to determine the safety of expectant treatment for localized disease. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：51 / 57

页数：7

共 35 条

[1] LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER [J].

ALBERTSEN, PC ;

FRYBACK, DG ;

STORER, BE ;

KOLON, TF ;

FINE, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :626-631

[2] Correlation of minute (0.5 mm or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: Role of prostate specific antigen density [J].

Allan, RW ;

Sanderson, H ;

Epstein, JI .

JOURNAL OF UROLOGY, 2003, 170 (02) :370-372

[3] Radical prostatectomy versus watchful waiting in early prostate cancer [J].

Bill-Axelson, A ;

Holmberg, L ;

Ruutu, M ;

Häggman, M ;

Andersson, SO ;

Bratell, S ;

Spångberg, A ;

Busch, C ;

Nordling, S ;

Garmo, H ;

Palmgren, J ;

Adami, HO ;

Norlén, BJ ;

Johansson, JE .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984

[4] Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era [J].

Carter, CA ;

Donahue, T ;

Sun, L ;

Wu, HG ;

McLeod, DG ;

Amling, C ;

Lance, R ;

Foley, J ;

Sexton, W ;

Kusuda, L ;

Chung, A ;

Soderdahl, D ;

Jackman, S ;

Moul, JW .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :4001-4008

[5] Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results [J].

Carter, HB ;

Walsh, PC ;

Landis, P ;

Epstein, JI .

JOURNAL OF UROLOGY, 2002, 167 (03) :1231-1234

[6] Prospective evaluation of men with stage T1c adenocarcinoma of the prostate [J].

Carter, HB ;

Sauvageot, J ;

Walsh, PC ;

Epstein, JI .

JOURNAL OF UROLOGY, 1997, 157 (06) :2206-2209

[7] Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression [J].

Choo, R ;

Klotz, L ;

Danjoux, C ;

Morton, GC ;

DeBoer, G ;

Szumacher, E ;

Fleshner, N ;

Bunting, P ;

Hruby, G .

JOURNAL OF UROLOGY, 2002, 167 (04) :1664-1669

[8]

CREEVY C D, 1951, J Urol, V65, P976

[9] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].

D'Amico, AV ;

Whittington, R ;

Malkowicz, SB ;

Schultz, D ;

Blank, K ;

Broderick, GA ;

Tomaszewski, JE ;

Renshaw, AA ;

Kaplan, I ;

Beard, CJ ;

Wein, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974

[10] Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].

D'Amico, AV ;

Chen, MH ;

Roehl, KA ;

Catalona, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135

← 1 2 3 4 →